Shares of Athira Pharma Inc. (ATHA) are down nearly 62% from their all-time high of $34.25, recorded last January, and trade around $13. The company has an important catalyst to watch this year.
Athira is a late clinical-stage biopharmaceutical developing small molecules to restore neuronal health and stop neurodegeneration. The lead therapeutic candidate is ATH-1017, being developed for Alzheimer's and Parkinson's disease dementia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com